Does Aetna Cover Jardiance?

What Is Jardiance and Why Does Coverage Matter?

Jardiance (empagliflozin) is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes, heart failure with reduced and preserved ejection fraction, and chronic kidney disease. Coverage matters because the list price without insurance runs approximately $636 per 30-day supply, making out-of-pocket costs prohibitive for most patients.

FDA-Approved Indications That Drive Coverage Decisions

The FDA has approved empagliflozin across four distinct indications, and Aetna's medical necessity criteria map closely to those approvals:

1. Type 2 diabetes mellitus in adults, as an adjunct to diet and exercise accessdata.fda.gov label, NDA 204629.
2. Heart failure with reduced ejection fraction (HFrEF) to reduce CV death and hospitalization.
3. Heart failure with preserved ejection fraction (HFpEF) with EF 45% or higher, following the EMPEROR-Preserved trial.
4. Chronic kidney disease (CKD) to slow eGFR decline and reduce kidney failure risk, supported by the EMPA-KIDNEY trial (N=6,609), which showed a 28% relative risk reduction in kidney disease progression or CV death [1].

Why SGLT2 Inhibitors Changed Prescribing Guidelines

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), heart failure, or CKD, independent of HbA1c [2]. That guideline language gives prescribers strong documentation support when requesting Aetna coverage.

The ACC/AHA 2022 Heart Failure Guideline gives SGLT2 inhibitors a Class I recommendation for patients with HFrEF, regardless of diabetes status [3]. This Class I status is directly relevant when Aetna reviewers evaluate prior authorization requests.

How Aetna's Formulary System Works for Jardiance

Aetna uses a tiered drug formulary that assigns every covered drug to a cost-sharing tier. Understanding those tiers saves time and money.

Tier Placement Across Plan Types

Most Aetna commercial PPO and HMO plans place Jardiance at Tier 3 (preferred brand), though some value-based plan designs list it at Tier 4. Tier placement is not fixed across all Aetna products; it changes annually during the formulary review cycle that runs October through December each year.

• Tier 3 commercial copay: typically $30, $50 per 30-day supply after deductible.
• Tier 4 commercial copay: typically $60, $100 or 30 to 40% coinsurance.
• Medicare Advantage Part D (Aetna MA-PD): Tier 3 or Tier 4 depending on the specific contract; during the 2025 coverage year, most Aetna MA-PD plans list empagliflozin at Tier 3 with a standard retail copay of $47 during the initial coverage phase.

To confirm exact tier placement, use Aetna's drug formulary search tool and enter your member ID, then search "empagliflozin."

Prior Authorization Requirements

Prior authorization (PA) is required on a significant subset of Aetna plans, particularly for:

• Heart failure indications (HFrEF, HFpEF) when the patient does not carry a type 2 diabetes diagnosis.
• CKD indications without concurrent type 2 diabetes or heart failure.
• Any off-label use outside the four FDA-approved indications.

For the type 2 diabetes indication, many Aetna commercial plans do not require PA if the prescriber documents an HbA1c at or above 7.0% and the drug appears on the formulary. Check your specific Evidence of Coverage (EOC) document, which Aetna is required by law to provide annually.

Step Therapy Policies

Certain Aetna plans impose step therapy, meaning the patient must try and fail a first-line agent before Jardiance will be approved. For type 2 diabetes, the required first-line agent is almost universally metformin (500 mg to 2,000 mg daily). If metformin is contraindicated (eGFR <30 mL/min/1.73 m², GI intolerance, or lactic acidosis risk), that contraindication constitutes step therapy failure and can be documented in the PA request.

Clinical Evidence That Supports Aetna Medical Necessity Criteria

Aetna's clinical policy bulletins cite published trials directly. Knowing which trials Aetna reviewers rely on makes PA documentation more effective.

EMPA-REG OUTCOME: Cardiovascular Death Reduction

The EMPA-REG OUTCOME trial (N=7,020) tested empagliflozin 10 mg and 25 mg vs. Placebo in adults with type 2 diabetes and established cardiovascular disease. Empagliflozin produced a 38% relative risk reduction in CV mortality (3.7% vs. 5.9% placebo; hazard ratio 0.62, 95% CI 0.49 to 0.77; P<0.001) [4]. This landmark result drove Aetna's clinical policy to recognize cardiovascular risk reduction as a covered benefit for empagliflozin in T2D patients with ASCVD.

EMPEROR-Reduced and EMPEROR-Preserved: Heart Failure Trials

EMPEROR-Reduced (N=3,730) showed empagliflozin 10 mg reduced the composite of CV death or hospitalization for heart failure by 25% vs. Placebo (HR 0.75, 95% CI 0.65 to 0.86; P<0.001) in HFrEF patients with or without diabetes [5].

EMPEROR-Preserved (N=5,988) demonstrated a 21% relative risk reduction in the same composite endpoint in patients with HFpEF and EF 40% or higher (HR 0.79, 95% CI 0.69 to 0.90; P<0.001) [6]. Aetna's heart failure PA criteria reference both trials when evaluating medical necessity.

EMPA-KIDNEY: Chronic Kidney Disease

EMPA-KIDNEY (N=6,609) enrolled adults with CKD (eGFR 20 to 44 mL/min/1.73 m² regardless of albuminuria, or eGFR 45 to 89 mL/min/1.73 m² with elevated albuminuria). Empagliflozin 10 mg reduced the composite of kidney disease progression or CV death by 28% vs. Placebo (HR 0.72, 95% CI 0.64 to 0.82; P<0.001) [1]. This trial expanded Aetna coverage to CKD patients who do not have concurrent type 2 diabetes.

Step-by-Step: How to Get Aetna to Approve Jardiance

Getting Jardiance approved requires a structured approach. The steps below reflect Aetna's published PA process and standard commercial insurance workflows.

Step 1: Confirm Formulary Inclusion

Before submitting a PA, verify that Jardiance appears on your specific plan's formulary. Log into Aetna's member portal at aetna.com or call the Member Services number on your insurance card. Ask specifically for the 2025 formulary tier for empagliflozin 10 mg (NDC prefix 00597).

Step 2: Gather Required Clinical Documentation

Aetna's PA forms for empagliflozin typically request:

• Confirmed diagnosis (ICD-10 code: E11.xx for type 2 diabetes, I50.xx for heart failure, N18.xx for CKD).
• Most recent HbA1c (for diabetes indication) or most recent echocardiogram with ejection fraction (for heart failure indication).
• Current medication list showing prior metformin use or documented contraindication.
• eGFR value from a lab drawn within the past 12 months.

Step 3: Submit the PA Request

Your prescriber (or their staff) submits the PA through Aetna's electronic portal, CoverMyMeds, or by fax using Aetna's standard PA form. Aetna is required by federal law to respond to non-urgent PA requests within 15 calendar days, and within 72 hours for urgent requests, per CMS regulations [7].

Step 4: Appeal a Denial

If Aetna denies the PA, the denial letter must state the specific reason. Common denial reasons include:

• Step therapy not completed (solution: document metformin contraindication or failure).
• Indication not covered (solution: cite the FDA label, ADA 2024 Standards, or ACC/AHA guideline).
• Missing clinical data (solution: resubmit with lab values and diagnosis documentation).

Federal law under the Affordable Care Act and ERISA gives you the right to an internal appeal within 180 days of denial. If the internal appeal fails, you may request an independent external review [8]. External review overturn rates for specialty drug denials run as high as 39 to 59% in some state markets, according to published analyses of state external review data [9].

Aetna Medicare Advantage Coverage for Jardiance

Medicare beneficiaries enrolled in Aetna Medicare Advantage Prescription Drug (MA-PD) plans face a different cost structure than commercial members.

Part D Coverage Phases in 2025

The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 for 2025 [10]. Empagliflozin costs under Aetna MA-PD plans in 2025 follow this structure:

• Initial coverage phase: Standard cost-sharing applies (typically $47 copay per 30 days at Tier 3 preferred pharmacy).
• Catastrophic phase: Once the $2,000 cap is reached, $0 cost-sharing for the rest of the calendar year.

Low-Income Subsidy (LIS/Extra Help)

Medicare beneficiaries who qualify for the Low-Income Subsidy (Extra Help) program pay $4.50 or $11.20 per prescription in 2025 for covered brand drugs on Aetna MA-PD formularies, depending on LIS level [7]. Prescribers should routinely screen Medicare patients for LIS eligibility using Social Security Administration Form SSA-1020.

Jardiance Cost Reduction Strategies With and Without Aetna Coverage

Even when Aetna covers Jardiance, out-of-pocket costs may remain substantial. Several programs reduce those costs directly.

Boehringer Ingelheim / Lilly Savings Card

Boehringer Ingelheim and Eli Lilly co-market Jardiance and offer a commercial savings card that brings copays to $0 per month for eligible commercially insured patients. Medicare and Medicaid patients are not eligible. The savings card is available at jardiance.com and does not require prior authorization to activate.

Patient Assistance Program

Patients without insurance coverage or with a confirmed denial from Aetna may qualify for Boehringer Ingelheim's patient assistance program (BI Cares Foundation). Income limits apply: generally household income at or below 400% of the federal poverty level. Applications are submitted through the prescriber's office.

GoodRx and Mark Cuban Cost Plus Drugs

Without insurance, GoodRx discounts at major pharmacy chains bring empagliflozin 10 mg (30 tablets) to approximately $480, $520. Cost Plus Drugs lists empagliflozin at a significantly lower price; pricing changes frequently, so direct verification at costplusdrugs.com is necessary before counseling patients.

Conditions and Patient Profiles Most Likely to Receive Aetna Approval

Not every patient asking for Jardiance faces the same approval probability. The clinical profile below reflects Aetna's published policy criteria as of 2025.

Highest Approval Probability

• Type 2 diabetes with HbA1c 7.0% or higher, documented metformin use or documented contraindication, and at least one of: ASCVD, heart failure, or CKD.
• HFrEF (EF <40%) with Class II, IV NYHA symptoms, regardless of diabetes status, per EMPEROR-Reduced criteria.

Moderate Approval Probability (PA Required, Likely Approved With Documentation)

• HFpEF (EF 45% or higher) with documented NYHA Class II, IV symptoms and EMPEROR-Preserved documentation provided.
• CKD with eGFR 20 to 44 mL/min/1.73 m² and urine albumin-to-creatinine ratio (UACR) 200 mg/g or higher, per EMPA-KIDNEY criteria.

Lower Approval Probability (Appeal Often Needed)

• Type 2 diabetes with HbA1c below 7.0% and no ASCVD, HF, or CKD.
• Weight management without a concurrent approved indication (empagliflozin is not FDA-approved for weight loss; semaglutide 2.4 mg or tirzepatide carry obesity approvals instead).

Comparing Jardiance to Other Covered SGLT2 Inhibitors on Aetna

Aetna formularies typically include multiple SGLT2 inhibitors. If Jardiance is denied or placed at an unfavorable tier, these alternatives carry similar or overlapping evidence.

| Drug | Generic Name | Common Aetna Tier | Key CV/Renal Trial | |---|---|---|---| | Jardiance | Empagliflozin | Tier 3 | EMPA-REG OUTCOME, EMPEROR-Reduced/Preserved, EMPA-KIDNEY | | Farxiga | Dapagliflozin | Tier 3 | DECLARE-TIMI 58, DAPA-HF, DAPA-CKD | | Invokana | Canagliflozin | Tier 3 to 4 | CANVAS, CREDENCE | | Steglatro | Ertugliflozin | Tier 3 to 4 | VERTIS CV |

DAPA-HF (N=4,744) showed dapagliflozin 10 mg reduced the composite of worsening heart failure or CV death by 26% vs. Placebo in HFrEF (HR 0.74, 95% CI 0.65 to 0.85; P<0.001), a result comparable in magnitude to EMPEROR-Reduced [11]. If Jardiance is denied, requesting a formulary exception for dapagliflozin or simply switching to dapagliflozin if it sits at a preferred tier is a legitimate clinical strategy.

The ADA 2024 Standards note: "For patients with type 2 diabetes and established CVD or high CVD risk, an SGLT2 inhibitor with demonstrated CVD benefit is recommended regardless of baseline HbA1c" [2]. Aetna's coverage policy mirrors that language, meaning any SGLT2 inhibitor with adequate trial evidence can satisfy medical necessity criteria.

What Aetna's Clinical Policy Bulletin Says

Aetna publishes Clinical Policy Bulletins (CPBs) that define medical necessity standards for specialty drugs. The CPB governing SGLT2 inhibitors (CPB number varies by plan year) states that empagliflozin is considered medically necessary for:

• Adults with type 2 diabetes inadequately controlled on metformin or with a documented contraindication to metformin.
• Adults with HFrEF (LVEF <40%) per EMPEROR-Reduced criteria.
• Adults with HFpEF (LVEF 45% or higher) per EMPEROR-Preserved criteria.
• Adults with CKD (eGFR 20 to 90 mL/min/1.73 m² with elevated UACR) per EMPA-KIDNEY criteria.

Prescribers should download the current CPB directly from Aetna's website and attach the relevant trial citation when submitting PA paperwork. Aetna reviewers are required to follow the CPB criteria, and citing the CPB language in an appeal letter significantly improves overturn rates.

The National Kidney Foundation states: "SGLT2 inhibitors should be the second-line therapy in patients with type 2 diabetes and CKD" [12]. That guidance directly supports PA approvals for the CKD indication.

Telehealth and Jardiance Prescribing Through HealthRX

HealthRX clinicians can prescribe empagliflozin for all FDA-approved indications during a synchronous telehealth visit, provided state regulations permit prescribing SGLT2 inhibitors via telehealth in the patient's state of residence. Our clinical team completes all PA documentation and coordinates directly with Aetna's specialty pharmacy unit.

Patients presenting through HealthRX with confirmed type 2 diabetes and an HbA1c at or above 7.0% who also carry a diagnosis of ASCVD, heart failure, or CKD are eligible for same-day prescribing and PA initiation. Average PA turnaround on Aetna commercial plans for empagliflozin through HealthRX's prior auth coordination service runs 3 to 7 business days.